Blueprint
 
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending 20 January 2017
 
GlaxoSmithKline plc
(Name of registrant)

 
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

 
 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

 
 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

 
 
 
Yes      No x
 
 
 
 
 
GlaxoSmithKline plc (the ‘Company’)
 
Transaction notification
 
1.
 
Details of PDMR/person closely associated with them (‘PCA’)
 
a)
 
Name
 
Dr M M Slaoui
 
b)
 
Position/status
 
Chairman, Global Vaccines
 
c)
 
Initial notification/
amendment
Initial notification
 
2.
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
 
Name
 
GlaxoSmithKline plc
 
b)
 
LEI
 
5493000HZTVUYLO1D793
 
3.
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
 
Description of the financial instrument
 
American Depositary Shares (‘ADSs’)
ISIN: US37733W1053
 
b)
 
Nature of the transaction
 
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 12 January 2017.
 
c)
 
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
$38.9854
 
11.660
 
d)
 
Aggregated information
 
Aggregated volume Price
 
n/a (single transaction)
 
 
e)
 
Date of the transaction
 
2017-01-19
 
f)
 
Place of the transaction
 
New York Stock Exchange (XNYS)
 
1.
 
Details of PDMR/person closely associated with them (‘PCA’)
 
a)
 
Name
 
Mr B McNamara
 
b)
 
Position/status
 
CEO, Consumer Healthcare
 
c)
 
Initial notification/
amendment
Initial notification
 
2.
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
 
Name
 
GlaxoSmithKline plc
 
b)
 
LEI
 
5493000HZTVUYLO1D793
 
3.
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
 
Description of the financial instrument
 
American Depositary Shares (‘ADSs’)
ISIN: US37733W1053
 
b)
 
Nature of the transaction
 
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 12 January 2017.
 
c)
 
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
$38.9854
 
9.002
 
d)
 
Aggregated information
 
Aggregated volume Price
 
n/a (single transaction)
 
e)
 
Date of the transaction
 
2017-01-19
 
f)
 
Place of the transaction
 
New York Stock Exchange (XNYS)
 
1.
 
Details of PDMR/person closely associated with them (‘PCA’)
 
a)
 
Name
 
Mr D E Troy
 
b)
 
Position/status
 
SVP & General Counsel
 
c)
 
Initial notification/
amendment
Initial notification
 
2.
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
 
Name
 
GlaxoSmithKline plc
 
b)
 
LEI
 
5493000HZTVUYLO1D793
 
3.
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
 
Description of the financial instrument
 
American Depositary Shares (‘ADSs’)
ISIN: US37733W1053
 
b)
 
Nature of the transaction
 
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 12 January 2017.
 
c)
 
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
$38.9854
 
1274.559
 
d)
 
Aggregated information
 
Aggregated volume Price
 
n/a (single transaction)
e)
 
Date of the transaction
 
2017-01-19
 
f)
 
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
1.
 
Details of PDMR/person closely associated with them (‘PCA’)
 
a)
 
Name
 
Dr K Slaoui
 
b)
 
Position/status
 
PCA of Dr M M Slaoui (Chairman, Global Vaccines)
 
c)
 
Initial notification/
amendment
Initial notification
 
2.
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
 
Name
 
GlaxoSmithKline plc
 
b)
 
LEI
 
5493000HZTVUYLO1D793
 
3.
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
 
Description of the financial instrument
 
American Depositary Shares (‘ADSs’)
ISIN: US37733W1053
 
b)
 
Nature of the transaction
 
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 12 January 2017.
 
c)
 
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
$38.9854
 
28.122
 
d)
 
Aggregated information
 
Aggregated volume Price
 
n/a (single transaction)
 
e)
 
Date of the transaction
 
2017-01-19
 
f)
 
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

 
GlaxoSmithKline plc
 
(Registrant)
 
 
Date: January 20, 2017 
 
 
 
 
By: VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GlaxoSmithKline plc